Polycystic ovary syndrome: Insights into the therapeutic approach with inositols

Frontiers in Pharmacology

Volumn 8, Issue JUN, 2017, Pages

  Sortino, Maria A ^a   Salomone, Salvatore ^a   Carruba, Michele O ^b   Drago, Filippo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

D chiro inositol; Inositol; Insulin resistance; Myo inositol; Polycystic ovary syndrome

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID; INOSITOL; MUELLERIAN INHIBITING FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PYRUVATE DEHYDROGENASE;

ANDROGEN SYNTHESIS; BIOGENESIS; CORPUS LUTEUM; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL FACTOR; ENZYME REGULATION; GLUCOSE METABOLISM; GRANULOCYTE; HUMAN; HYDROLYSIS; IN VITRO FERTILIZATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISOMERIZATION; LUTEINIZATION; MENSTRUAL CYCLE; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; OVULATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PHYSICAL ACTIVITY; PROTEIN EXPRESSION; PROTEIN METABOLISM; REVIEW; SIGNAL TRANSDUCTION; SOCIOECONOMICS; STEROIDOGENESIS; TISSUE DISTRIBUTION;

EID: 85020771343     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00341     Document Type: Review

References (121)

1. Artini, P. G., Di Berardino, O. M., Papini, F., Genazzani, A. D., Simi, G., Ruggiero, M., et al. (2013). Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol. Endocrinol. 29, 375-379. doi: 10.3109/09513590.2012.743020
2. Asplin, I., Galasko, G., and Larner, J. (1993). Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol-and the myoinositol containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc. Natl. Acad. Sci. U.S.A. 90, 5924-5928. doi: 10.1073/pnas.90.13.5924
3. Asuncion, M., Calvo, R. M., SanMillan, J. L., Sancho, J., Avila, S., and Escobar-Morreale, H. F. (2000). A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 85, 2434-2438. doi: 10.1210/jcem.85.7.6682
4. Azziz, R., Marin, C., Hoq, L., Badamgarav, E., and Song, P. (2005). Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J. Clin. Endocrinol. Metab. 90, 4650-4658. doi: 10.1210/jc.2005-0628
5. Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., and Yildiz, B. O. (2004). The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89, 2745-2749. doi: 10.1210/jc.2003-032046
6. Baillargeon, J. P., Diamanti-Kandarakis, E. R., Ostlund, E. Jr., Apridonidze, T., Iuorno, M. J., and Nestler, J. E. (2006). Altered D-chiroinositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 29, 300-305. doi: 10.2337/diacare.29.02.06.dc05-1070
7. Baillargeon, J. P., Iuorno, M. J., Apridonidze, T., and Nestler, J. E. (2010). Uncoupling between insulin and release of a d-chiro-inositol containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab. Syndr. Relat. Disord. 8, 127-136. doi: 10.1089/met.2009.0052
8. Baillargeon, J. P., Iuorno, M. J., and Nestler, J. E. (2003). Insulin sensitizers for polycystic ovary syndrome. Clin. Obstet. Gynecol. 46, 325-340. doi: 10.1097/00003081-200306000-00011
9. Baillargeon, J. P., Nestler, J. E., Ostlund, R. E., Apridonidze, T., and Diamanti-Kandarakis, E. (2008). Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum. Reprod. 23, 1439-1446. doi: 10.1093/humrep/den097
10. Bausenwein, J., Serke, H., Eberle, K., Hirrlinger, J., Jogschies, P., Hmeidan, F. A., et al. (2010). Elevated levels of oxidized low-density lipoprotein and of catalase activity in follicular fluid of obese women. Mol. Hum. Reprod. 2, 117-124. doi: 10.1093/molehr/gap078
11. Borruel, S., Fernández-Durán, E., Alpañés, M., Martí, D., álvarez-Blasco, F., Luque-Ramírez, M., et al. (2013). Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J. Clin. Endocrinol. Metab. 98, 1254-1263. doi: 10.1210/jc.2012-3698
12. Bourgeois, F., Coady, M. J., and Lapointe, J. Y. (2005). Determination of transport stoichiometry for two cation coupled myo-inositol cotransporters: SMIT2 and HMIT. J. Physiol. 563, 333-343. doi: 10.1113/jphysiol.2004.076679
13. Cadagan, D., Khan, R., and Amer, S. (2016). Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. Reprod. Biol. 16, 53-60. doi: 10.1016/j.repbio.2015.12.006
14. Carlomagno, G., and Unfer, V. (2011). Inositol safety: clinical evidences. Eur. Rev. Med. Pharmacol. Sci. 15, 931-936
15. Carlomagno, G., Unfer, V., Benvenga, S., and Nestler, J. E. (2015). Myo-inositol: with or without. Endocr. J. 62, 297-298. doi: 10.1507/endocrj.EJ14-0566
16. Carlomagno, G., Unfer, V., and Roseff, S. (2011). The D-chiro-inositol paradox in the ovary. Fertil. Steril. 95, 2515-2516. doi: 10.1016/j.fertnstert.2011.05.027
17. Chattopadhayay, R., Ganesh, A., Samanta, J., Jana, S. K., Chakravarty, B. N., and Chaudhury, K. (2010). Effect of follicular fluid oxidative stress on meiotic spindle formation in infertile women with polycystic ovarian syndrome. Gynecol. Obstet. Invest. 69, 197-202. doi: 10.1159/000270900
18. Cheang, K. I., Baillargeon, J. P., Essah, P. A., Ostlund, R. E. Jr., Apridonize, T., Islam, L., et al. (2008). Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 57, 1390-1397. doi: 10.1016/j.metabol.2008.05.008
19. Chen, Z. J., Zhao, H., He, L., Shi, Y., Qin, Y., Shi, Y., et al. (2011). Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat. Genet. 43, 55-59. doi: 10.1038/ng.732
20. Cianci, A., Panella, M., Fichera, M., Falduzzi, C., Bartolo, M., and Caruso, S. (2015). D-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. Gynecol. Endocrinol. 31, 83-86. doi: 10.3109/09513590.2015.1014784
21. Ciotta, L., Stracquadanio, M., Pagano, I., Carbonaro, A., Palumbo, M., and Gulino, F. (2011). Effects of Myo-Inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. Eur. Rev. Med. Pharmacol. Sci. 15, 509-514
22. Coady, M. J., Wallendorff, B. D., Gagnon, G., and Lapointe, J. Y. (2002). Identification of a novel Na+/myo-inositol cotransporter. J. Biol. Chem. 277, 35219-35224. doi: 10.1074/jbc.M204321200
23. Colazingari, S., Treglia, M., Najjar, R., and Bevilacqua, A. (2013). The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiroinositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch. Gynecol. Obstet. 288, 1405-1411. doi: 10.1007/s00404-013-2855-3
24. Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., et al. (2014). European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest group's questionnaire. Eur. J. Endocrinol. 171, 489-498. doi: 10.1530/EJE-14-0252
25. Costantino, D., Minozzi, G., Minozzi, E., and Guaraldi, C. (2009). Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur. Rev. Med. Pharmacol. Sci. 13, 105-110
26. Croze, M. L., and Soulage, C. O. (2013). Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 95, 1811-1827. doi: 10.1016/j.biochi.2013.05.011
27. Cusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M. E., Pratipanawatr, T., et al. (2000). Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J. Clin. Invest. 105, 311-320. doi: 10.1172/JCI7535
28. Dang, N. T., Mukai, R., Yoshida, K., and Ashida, H. (2010). D-pinitol and myo-inositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 mice. Biosci. Biotechnol. Biochem. 74, 1062-1067. doi: 10.1271/bbb.90963
29. Daughaday, W. H., and Larner, J. (1954). The renal excretion of inositol in normal and diabetic human beings. J. Clin. Invest. 33, 326-332. doi: 10.1172/JCI102901
30. De Leo, V., Musacchio, M. C., Cappelli, V., Massaro, M. G., Morgante, G., and Petraglia, F. (2016). Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod. Biol. Endocrinol. 14, 38. doi: 10.1186/s12958-016-0173-x
31. Di Nicola, S., Chiu, T. T., Unfer, V., Carlomagno, G., and Bizzarri, M. (2014). The rationale of the myo-inositol and d-chiro-inositol combined treatment for polycystic ovary syndrome. J. Clin. Pharmacol. 54, 1079-1092. doi: 10.1002/jcph.362
32. Di Paolo, G., and De Camilli, P. (2006). Phosphoinositides in cell regulation and membrane dynamics. Nature 443, 651-657. doi: 10.1038/nature05185
33. Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., et al. (1999). Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103, 253-259. doi: 10.1172/JCI5001
34. Du, J., Wang, J., Sun, X., Xu, X., Zhang, F., Wang, B., et al. (2014). Family-based analysis of INSR polymorphisms in Chinese PCOS. Reprod. Biomed. 29, 239-244. doi: 10.1016/j.rbmo.2014.03.028
35. Dunaif, A., Segal, K. R., Futterweit, W., and Dobrjansky, A. (1989). Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes Metab. Res. Rev. 38, 1165-1174. doi: 10.2337/diab.38.9.1165
36. El Hayek, S., Bitar, L., Hamdar, L. H., Mirza, F. G., and Daoud, G. (2016). Poly cystic ovarian syndrome: an updated overview. Front. Physiol. 7:124. doi: 10.3389/fphys.2016.00124
37. Fauser, B. C., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., et al. (2012). Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS consensus workshop group. Fertil. Steril. 97, 28-38. doi: 10.1016/j.fertnstert.2011.09.024
38. Formuso, C., Stracquadanio, M., and Ciotta, L. (2015). Myo-inositol vs. D-chiro inositol in PCOS treatment. Minerva Ginecol. 67, 321-325
39. Franks, S., Gharani, N., Waterworth, D., Batty, S., White, D., Williamson, R., et al. (1997). The genetic basis of polycystic ovary syndrome. Hum. Reprod. 12, 2641-2648. doi: 10.1093/humrep/12.12.2641
40. Genazzani, A. D., Lanzoni, C., Ricchieri, F., and Jasonni, V. M. (2008). Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol. Endocrinol. 24, 139-144. doi: 10.1080/09513590801893232
41. Genazzani, A. D., Petraglia, F., Pianazzi, F., Volpogni, C., and Genazzani, A. R. (1993). The concomitant release of androstenedione with cortisol and luteinizing hormone pulsatile releases distinguishes adrenal from ovarian hyperandrogenism. Gynecol. Endocrinol. 7, 33-41. doi: 10.3109/09513599309152477
42. Genazzani, A. D., Prati, A., Santagni, S., Ricchieri, F., Chierchia, E., Rattighieri, E., et al. (2012). Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol. Endocrinol. 28, 969-973. doi: 10.3109/09513590.2012.685205
43. Genazzani, A. D., Santagni, S., Rattighieri, E., Chierchia, E., Despini, G., Marini, G., et al. (2014). Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol. Endocrinol. 30, 438-443. doi: 10.3109/09513590.2014.897321
44. Gerli, S., Mignosa, M., and Di Renzo, G. C. (2003). Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur. Rev. Med. Pharmacol. Sci. 7, 151-159
45. Gerli, S., Papaleo, E., Ferrari, A., and di Renzo, G. C. (2007). Randomized, double blind placebo-controlled trial: effects of Myoinositol on ovarian function and metabolic factors in women with PCOS. Eur. Rev. Med. Pharmacol. Sci. 11, 347-354
46. González, F., Nair, K. S., Daniels, J. K., Basal, E., Schimke, J. M., and Blair, H. E. (2012). Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. J. Clin. Endocrinol. Metab. 97, 2836-2843. doi: 10.1210/jc.2012-1259
47. González, S., Sia, C. L., Shepard, M. H., Rote, N. S., and Minuim, J. (2012). Hyperglycemia-induced oxidative stress is independent of excess abdominal adiposity in normal-weight women with polycystic ovary syndrome. Hum. Reprod. 27, 3560-3568. doi: 10.1093/humrep/des320
48. Greene, D. A., and Lattimer, S. A. (1982). Sodium-and energy-dependent uptake of myo-inositol by rabbit peripheral nerve. Competitive inhibition by glucose and lack of an insulin effect. J. Clin. Invest. 70, 1009-1018. doi: 10.1172/JCI110688
49. Hasegawa, R., and Eisenberg, F. Jr. (1981). Selective hormonal control of myo-inositol biosynthesis in reproductive organs and liver of the male rat. Proc. Natl. Acad. Sci. U.S.A. 78, 4863-4866. doi: 10.1073/pnas.78.8.4863
50. Heimark, D., McAllister, J., and Larner, J. (2014). Decreased myoinositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr. J. 61, 111-117. doi: 10.1507/endocrj.EJ13-0423
51. Højlund, K. (2014). Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance. Dan. Med. J. 61, B4890
52. Homburg, R., Ray, A., Bhide, P., Gudi, A., Shah, A., Timms, P., et al. (2013). The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum. Reprod. 28, 1077-1083. doi: 10.1093/humrep/det015
53. Hong, J. H., Jang, H. W., Kang, Y. E., Lee, J. H., Kim, K. S., Kim, H. J., et al. (2012). Urinary chiro-and myo-inositol levels as a biological marker for type 2 diabetes mellitus. Dis. Markers 33, 193-199. doi: 10.3233/DMA-2012-0925 PMID:22960342
54. Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J. P., Dillon, P., Gunn, R. D., Allan, G., et al. (2002). Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr. Pract. 8, 417-423. doi: 10.4158/EP.8.6.417
55. Joham, A. E., Teede, H. J., Ranasinha, S., Zoungas, S., and Boyle, J. (2015). Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study. J. Womens Health (Larchmt) 24, 299-307. doi: 10.1089/jwh.2014.5000
56. Kamenov, Z., Kolarov, G., Gateva, A., Carlomagno, G., and Genazzani, A. D. (2015). Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol. Endocrinol. 31, 131-135. doi: 10.3109/09513590.2014.964640
57. Karabulut, A., Yaylali, G. F., Demirlenk, S., Sevket, O., and Acun, A. (2012). Evaluation of body fat distribution in PCOS and its association with carotid atherosclerosis and insulin resistance. Gynecol. Endocrinol. 28, 111-114. doi: 10.3109/09513590.2011.589929
58. Kawa, J. M., Przybylski, R., and Taylor, C. G. (2003). Urinary chiro-inositol and myoinositol excretion is elevated in the diabetic db/db mouse and streptozotocin diabetic rat. Exp. Biol. Med. (Maywood). 228, 907-914
59. Kennington, A. S., Hill, C. R., Craig, J., Bogardus, C., Raz, I., Ortmeyer, H. K., et al. (1990). Low urinary chiroinositol excretion in non-insulin-dependent diabetes mellitus. N. Eng. J. Med. 323, 373-378. doi: 10.1056/NEJM199008093230603
60. Kirschner, M. A., Samojlik, E., Drejka, M., Szmal, E., Schneider, G., and Ertel, N. (1990). Androgen-estrogen metabolism in women with upper body versus lower body obesity. J. Clin. Endocrinol. Metab. 70, 473-479. doi: 10.1210/jcem-70-2-473
61. Kollros, P. E., Goldstein, G. W., and Betz, A. L. (1990). Myo-inositol transport into endothelial cells derived from nervous system microvessels. Brain Res. 511, 259-264. doi: 10.1016/0006-8993(90)90170-G
62. Kulshreshtha, B., Singh, S., and Arora, A. (2013). Family background of Diabetes Mellitus, obesity and hypertension affects the phenotype and first symptom of patients with PCOS. Gynecol. Endocrinol. 29, 1040-1044. doi: 10.3109/09513590.2013.829446
63. La Marca, A., Grisendi, V., Dondi, G., Sighinolfi, G., and Cianci, A. (2015). The menstrual cycle regularization following D-chiroinositol treatment in PCOS women: a retrospective study. Gynecol. Endocrinol. 31, 52-56. doi: 10.3109/09513590.2014.964201
64. Laganà, A. S., Barbaro, L., and Pizzo, A. (2015). Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch. Gynecol. Obstet. 291, 1181-1186. doi: 10.1007/s00404-014-3552-6
65. Lam, S., McWilliams, A., LeRiche, J., MacAulay, C., Wattenberg, L., and Szabo, E. (2006). A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol. Biomarkers. Prev. 15, 1526-1531. doi: 10.1158/1055-9965.EPI-06-0128
66. Langlais, P., Yi, Z., Finlayson, J., Luo, M., Mapes, R., De Filippis, E., et al. (2011). Global IRS-1 phosphorylation analysis in insulin resistance. Diabetologia 54, 2878-2889. doi: 10.1007/s00125-011-2271-9
67. Larance, M., Ramm, G., Stockli, J., van Dam, E. M., Winata, S., Wasinger, V., et al. (2005). Characterization of the role of the Rab GTPaseactivating protein AS160 in insulin-regulated GLUT4 trafficking. J. Biol. Chem. 280, 37803-37813. doi: 10.1074/jbc.M503897200
68. Larner, J. (2002). D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance. Int. J. Exp. Diabetes Res. 3, 47-60. doi: 10.1080/15604280212528
69. Larner, J., Brautigan, D. L., and Thorner, M. O. (2010). D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol. Med. 16, 543-552. doi: 10.2119/molmed.2010.00107
70. Larner, J., and Craig, J. W. (1996). Urinary myo-inositol-to-chiroinositol ratios and insulin resistance. Diabetes Care 19, 76-78. doi: 10.2337/diacare.19.1.76
71. Larner, J., Huang, L. C., Schwartz, C. F., Oswald, A. S., Shen, T. Y., and Kinter, M. (1988). Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphate contains galactosamine and D-chiroinositol. Biochem. Biophys. Res. Commun. 151, 1416-1426. doi: 10.1016/S0006-291X(88)80520-5
72. Lauretta, R., Lanzolla, G., Vici, P., Mariani, L., Moretti, C., and Appetecchia, M. (2016). Insulin-sensitizers, polycystic ovary syndrome and gynaecological cancer risk. Int. J. Endocrinol. 2016:8671762. doi: 10.1155/2016/8671762
73. Lazarenko, R., Geisler, J., Bayliss, D., Larner, J., and Li, C. (2014). D-chiro-inositol glycan stimulates insulin secretion in pancreatic β cells. Mol. Cell. Endocrinol. 387, 1-7. doi: 10.1016/j.mce.2014.02.004
74. Legro, R. S. (2016). Ovulation induction in polycystic ovary syndrome: current options. Best Pract. Res. Clin. Obstet. Gynaecol. 37, 152-159. doi: 10.1016/j.bpobgyn.2016.08.001
75. Liu, N., Ma, Y., Wang, S., Zhang, X., Zhang, Q., Zhang, X., et al. (2012). Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome. Reprod. Biol. Endocrinol. 10:36. doi: 10.1186/1477-7827-10-36
76. Loewus, M. W., Loewus, F. A., Brillinger, G. U., Otsuka, H., and Floss, H. G. (1980). Stereochemistry of the myo-inositol-1-phosphate synthase reaction. J. Biol. Chem. 255, 11710-11712
77. Minozzi, M., Costantino, D., Guaraldi, C., and Unfer, V. (2011). The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol. Endocrinol. 27, 920-924. doi: 10.3109/09513590.2011.564685
78. Minozzi, M., D'Andrea, G., and Unfer, V. (2008). Treatment of hirsutism with Myo-Inositol: a prospective clinical study. Reprod. BioMed. 17, 579-582. doi: 10.1016/S1472-6483(10)60248-9
79. Minozzi, M., Nordio, M., and Pajalich, R. (2013). The combined therapy myoinositol plus d-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur. Rev. Med. Pharmacol. Sci. 17, 537-540
80. Murri, M., Luque-Ramírez, M., Insenser, M., Ojeda-Ojeda, M., and Escobar-Morreale, H. F. (2013). Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum. Reprod. Update 19, 268-288. doi: 10.1093/humupd/dms059
81. Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., and Allan, G. (1999). Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N. Engl. J. Med. 340, 1314-1320. doi: 10.1056/NEJM199904293401703
82. Nestler, J. E., Reilly, E. R., Cheang, K. I., Bachmann, L. M., and Downs, R. W. Jr. (2012). A pilot study: effects of decreasing serum insulin with diazoxide on vitamin D levels in obese women with polycystic ovary syndrome. Trans. Am. Clin. Climatol. Assoc. 123, 209-219
83. Nisoli, E., Clementi, E., Carruba, M. O., and Moncada, S. (2007). Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ. Res. 100, 795-806. doi: 10.1161/01.res.0000259591.97107.6c
84. Nordio, M., and Proietti, E. (2012). The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur. Rev. Med. Pharmacol. Sci. 16, 575-581
85. Orio, F. Jr., Palomba, S., Spinelli, L., Cascella, T., Tauchmanovà, L., Zullo, F., et al. (2004). The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J. Clin. Endocrinol. Metab. 89, 3696-3701. doi: 10.1210/jc.2003-032049
86. Orio, F., and Palomba, S. (2014). Reproductive endocrinology: new guidelines for the diagnosis and treatment of PCOS. Nat. Rev. Endocrinol. 10, 130-132. doi: 10.1038/nrendo.2013.248
87. Pacchiarotti, A., Carlomagno, G., Antonini, G., and Pacchiarotti, A. (2016). Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol. Endocrinol. 32, 69-73. doi: 10.3109/09513590.2015.1101444
88. Pak, Y., Hong, Y., Kim, S., Piccariello, T., Farese, R. V., and Larner, J. (1998). In vivo chiro-Inositol metabolism in the rat: a defect in chiro-Inositol synthesis from myo-Inositol and an increased incorporation of chiro-[3H]Inositol into phospholipid in the Goto-Kakizaki (G.K.) rat. Mol. Cells 8, 301-309
89. Pak, Y., Huang, L. C., Lilley, K. J., and Larner, J. (1992). In vivo conversion of [3H]myoinositol to [3H]chiroinositol in rat tissues. J. Biol. Chem. 267, 16904-16910
90. Papaleo, E., Unfer, V., Baillargeon, J. P., De Santis, L., Fusi, F., Brigante, C., et al. (2007). Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol. Endocrinol. 23, 700-703. doi: 10.1080/09513590701672405
91. Pasquali, R., Stener-Victorin, E., Yildiz, B. O., Duleba, A. J., Hoeger, K., Mason, H., et al. (2011). PCOS forum: research in polycystic ovary syndrome today and tomorrow. Clin. Endocrinol. 74, 424-433. doi: 10.1111/j.1365-2265.2010.03956.x
92. Peppard, H. R., Marfori, J., Iuorno, M. J., and Nestler, J. E. (2001). Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 24, 1050-1052. doi: 10.2337/diacare.24.6.1050
93. Piomboni, P., Focarelli, R., Capaldo, A., Stendardi, A., Cappelli, V., Cianci, A., et al. (2014). Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin. J. Assist. Reprod. Genet. 31, 1269-1276. doi: 10.1007/s10815-014-0307-z
94. Piouka, A., Farmakiotis, D., Katsikis, I., Macut, D., Gerou, S., and Panidis, D. (2009). Anti-mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am. J. Physiol. Endocrinol. Metab. 296, E238-E243. doi: 10.1152/ajpendo.90684.2008
95. Pitkänen, E. (1976). Changes in serum and urinary myo-inositol levels in chronic glomerulonephritis. Clin. Chim. Acta 71, 461-468. doi: 10.1016/0009-8981(76)90097-8
96. Pizzo, A., Laganà, A. S., and Barbaro, L. (2014). Comparison between effects of myo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol. Endocrinol. 30, 205-208. doi: 10.3109/09513590.2013.860120
97. Preston, A. S., Yamauchi, A., Kwon, H. M., and Handler, J. S. (1995). Activators of protein kinase A and of protein kinase C inhibit MDCK cell myo-inositol and betaine uptake. J. Am. Soc. Nephrol. 6, 1559-1564
98. Prpic, V., Blackmore, P. F., and Exton, J. H. (1982). myo-Inositol uptake and metabolism in isolated rat liver cells. J. Biol. Chem. 257, 11315-11322. doi: 10.1093/humupd/dmq032
99. Qiao, J., and Feng, H. L. (2011). Extra-and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum. Reprod. Update 17, 17-33. doi: 10.1093/humupd/dmq032
100. Raffone, E., Rizzo, P., and Benedetto, V. (2010). Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol. Endocrinol. 26, 275-280. doi: 10.3109/09513590903366996
101. Rago, R., Marcucci, I., Leto, G., Caponecchia, L., Salacone, P., Bonanni, P., et al. (2015). Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study. J. Biol. Regul. Homeost Agents 29, 913-923
102. Sacchi, S., Marinaro, F., Tondelli, D., Lui, J., Xella, S., Marsella, T., et al. (2016). Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol. Reprod. Biol. Endocrinol. 14, 52. doi: 10.1186/s12958-016-0189-2
103. Sacchinelli, A., Venturella, R., Lico, L., Di Cello, A., Lucia, A., Rania, E., et al. (2014). the efficacy of inositol and N-acetyl cysteine administration (Ovaric HP) in improving the ovarian function in infertile women with PCOS with or without insulin resistance. Obstet. Gynecol. Int. 2014:141020. doi: 10.1155/2014/141020
104. Shimizu, K., Ida, T., Tsutsui, H., Asai, T., Otsubo, K., and Oku, N. (2010). Anti-obesity effect of phosphatidylinositol on diet-induced obesity in mice. J. Agric. Food Chem. 58, 11218-11225. doi: 10.1021/jf102075
105. Sleight, S., Wilson, B. A., Heimark, D. B., and Larner, J. (2002). G(q/11) is involved in insulin-stimulated inositol phosphoglycan putative mediator generation in rat liver membranes: co-localization of G(q/11) with the insulin receptor in membrane vesicles. Biochem. Biophys. Res. Commun. 295, 561-569. doi: 10.1016/S0006-291X(02)00701-5
106. Sun, T. H., Heimark, D. B., Nguygen, T., Nadler, J. L., and Larner, J. (2002). Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem. Biophys. Res. Commun. 293, 1092-1098. doi: 10.1016/S0006-291X(02)00313-3
107. Suzuki, S., Kawasaki, H., Satoh, Y., Ohtomo, M., Hirai, M., Hirai, A., et al. (1994). Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. Diabetes Care 17, 1465-1468. doi: 10.2337/diacare.17.12.1465
108. Tan, K., Kimber, W. A., Luan, J., Soos, M. A., Semple, R. K., Wareham, N. J., et al. (2007). Analysis of genetic variation in Akt2/PKB-beta in severe insulin resistance, lipodystrophy, type 2 diabetes, and related metabolic phenotypes. Diabetes Metab. Res. Rev. 56, 714-719. doi: 10.2337/db06-0921
109. Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., and Balen, A. H. (2012). Insulin sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiroinositol for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev. 16, CD003053. doi: 10.1002/14651858.CD003053.pub5
110. Taniguchi, C. M., Emanuelli, B., and Kahn, C. R. (2006). Critical nodes in signaling pathways: insights into insulin action. Nat. Rev. Mol. Cell. Biol. 7, 85-96. doi: 10.1038/nrm1837
111. The Rotterdam Eshre/Asrm-sponsored PCOS consensus workshop group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41-47
112. Toprak, S., Yönem, A., Akir, B. C., Güler, S., Azal, O., Ozata, M., et al. (2001). Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm. Res. 55, 65-70. doi: 10.1159/000049972
113. Uldry, M., Ibberson, M., Horisberger, J. D., Chatton, J. Y., Riederer, B. M., Thorens, B., et al. (2001). Identification of a mammalian H(+)-myo-inositol symporter expressed predominantly in the brain. EMBO J. 20, 4467-4477. doi: 10.1093/emboj/20.16.4467
114. Unfer, V., Carlomagno, G., Dante, G., and Facchinetti, F. (2012). Effects of myoinositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol. Endocrinol. 28, 509-515. doi: 10.3109/09513590.2011.650660
115. Unfer, V., Carlomagno, G., Papaleo, E., Vailati, S., Candiani, M., and Baillargeon, J. P. (2014). Hyperinsulinemia alters myo-inositol to D-chiro-inositol ratio in the follicular fluid of patients with PCOS. Reprod. Sci. 21, 854-858. doi: 10.1177/1933719113518985
116. Unfer, V., and Porcaro, G. (2014). Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev. Clin. Pharmacol. 7, 623-631. doi: 10.1586/17512433.2014.925795
117. Urbanek, M. (2007). The genetics of the polycystic ovary syndrome. Nat. Clin. Pract. Endocrinol. Metab. 3, 103-111. doi: 10.1038/ncpendmet0400
118. Valerio, A., Cardile, A., Cozzi, V., Bracale, R., Tedesco, L., Pisconti, A., et al. (2006). TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J. Clin. Invest. 116, 2791-2798. doi: 10.1172/JCI28570
119. Victor, V. M., Rocha, M., Bañuls, C., Sanchez-Serrano, M., Sola, E., Gomez, M., et al. (2009). Mitochondrial complex I impairment in leukocytes from polycystic ovary syndrome patients with insulin resistance. J. Clin. Endocrinol. Metab. 94, 3505-3512. doi: 10.1210/jc.2009-0466
120. Victor, V. M., Rovira-Llopis, S., Bañuls, C., Diaz-Morales, N., Castellò, R., Falcon, R., et al. (2015). Effects of metformin on mitochondrial function of leukocytes from polycystic ovary syndrome patients with insulin resistance. Eur. J. Endocrinol. 173, 683-691. doi: 10.1530/EJE-15-0572
121. Yap, A., Nishiumi, S., Yoshida, K-i., and Ashida, H. (2007). Rat L6 myotubes as an in vitro model system to study GLUT4-dependent glucose uptake stimulated by inositol derivatives. Cytotechnology 55, 103-108. doi: 10.1007/s10616-007-9107-y